Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
In this issue, we present another installment of our quarterly
review of pharmaceutical/biotechnology dealmaking—for the
third quarter of 2009. Our data come from Elsevier's Strategic
Transactions.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
